☆ 4.7 Article

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis

SCIENTIFIC REPORTS (2022)

Related references

Note: Only part of the references are listed.

Letter Oncology

Prevalence of unexplained erythrocytosis and thrombocytosis - an NHANES analysis

Douglas Tremblay et al.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Article Oncology

Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center

Daniel Davila-Gonzalez et al.

Summary: In a retrospective study on erythrocytosis, the use of isolated erythropoietin levels was found to be unreliable for screening causes, while JAK2 gene mutation status was a more reliable diagnostic method for polycythemia vera.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Review Oncology

Polycythemia vera: historical oversights, diagnostic details, and therapeutic views

Ayalew Tefferi et al.

Summary: Polycythemia vera (PV) is a relatively slow-growing myeloproliferative disorder with a long median survival, but it can be complicated by thrombotic, fibrotic, or leukemic events. Current treatment strategies focus on preventing thrombotic complications rather than prolonging survival or reducing the risk of leukemic or fibrotic progression. Cytoreductive therapy is recommended for high-risk or symptomatic low-risk disease.

LEUKEMIA (2021)

Add to Collection

Review Oncology

JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views

Naseema Gangat et al.

Summary: JAK2 unmutated or non-PV erythrocytosis includes hereditary and acquired conditions, which require a systematic diagnostic approach. Hereditary erythrocytosis necessitates family history documentation and laboratory screening, while acquired erythrocytosis is often due to hypoxia. Management should avoid cytoreductive therapy and phlebotomy should be based on symptom control rather than Hct threshold.

LEUKEMIA (2021)

Add to Collection

Review Genetics & Heredity

Genetic Background of Congenital Erythrocytosis

Mary Frances McMullin

Summary: Erythrocytosis can be primary or secondary, congenital or acquired, with most cases occurring in young patients or those with a family history. Clinical evaluation and management of congenital erythrocytosis are challenging, but venesection and low dose aspirin may be considered for treatment.

GENES (2021)

Add to Collection

Review Medicine, General & Internal

Investigation and management of erythrocytosis

Siraj Mithoowani et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

Add to Collection

Article Hematology

Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis

Hanneke J. C. M. Wouters et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

Christopher B. Benton et al.

CANCER (2019)

Add to Collection

Review Hematology

Update on mutations in the HIF: EPO pathway and their role in erythrocytosis

Terence R. Lappin et al.

BLOOD REVIEWS (2019)

Add to Collection

Article Hematology

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis A British Society for Haematology Guideline

Mary F. F. McMullin et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Review Oncology

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion

Tiziano Barbui et al.

BLOOD CANCER JOURNAL (2018)

Add to Collection

Article Oncology

Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera

Renbo Guo et al.

CHINESE JOURNAL OF CANCER (2017)

Add to Collection

Letter Hematology

Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera

Lucie Lanikova et al.

BLOOD (2016)

Add to Collection

Article Oncology

Epidemiology of myeloproliferative neoplasms in the United States

Jyotsna Mehta et al.

LEUKEMIA & LYMPHOMA (2014)

Add to Collection

Article Oncology

Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan

Jyotsna Mehta et al.

LEUKEMIA & LYMPHOMA (2014)

Add to Collection

Review Hematology

Erythrocytosis: the HIF pathway in control

Kristin Franke et al.

BLOOD (2013)

Add to Collection

Article Oncology

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection

Giada V. Zapparoli et al.

BMC CANCER (2013)

Add to Collection

Review Medicine, General & Internal

The diagnosis and management of erythrocytosis

Clodagh Keohane et al.

BMJ-BRITISH MEDICAL JOURNAL (2013)

Add to Collection

Article Dermatology

ICD-9-CM to ICD-10-CM Codes: What? Why? How?

Donna J. Cartwright

ADVANCES IN WOUND CARE (2013)

Add to Collection

Article Respiratory System

(Correcting) misdiagnoses of asthma: a cost effectiveness analysis

Smita Pakhale et al.

BMC PULMONARY MEDICINE (2011)

Add to Collection

Review Oncology

The complete evaluation of erythrocytosis: congenital and acquired

M. M. Patnaik et al.

LEUKEMIA (2009)

Add to Collection

Reprint Medicine, General & Internal

Chronic cyanosis, with polycythaemia and enlarged spleen: A new clinical entity (Reprinted from American Journal of the Medical Sciences, vol 125, 1903)

William Osler

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2008)

Add to Collection

Article Health Care Sciences & Services

Measuring diagnoses: ICD code accuracy

KJ O'Malley et al.

HEALTH SERVICES RESEARCH (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.